AAAAAA

   
Results: 1-14 |
Results: 14
SIMULATING CLINICAL-TRIALS WITH RIDO
Authors: HOLFORD N AMSTEIN R GASSER D GUENTERT TW KUTZERA S PECK C RACINE A ROHR HP STEIMER JL BUHLER FR
Citation: N. Holford et al., SIMULATING CLINICAL-TRIALS WITH RIDO, Clinical pharmacology and therapeutics, 63(2), 1998, pp. 132-132
PLASMA-LEVELS OF THE ENANTIOMERS OF THIORIDAZINE, THIORIDAZINE 2-SULFOXIDE, THIORIDAZINE 2-SULFONE, AND THIORIDAZINE 5-SULFOXIDE IN POOR AND EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN AND MEPHENYTOIN
Authors: EAP CB GUENTERT TW SCHAUBLINLOIDL M STABL M KOEB L POWELL K BAUMANN P
Citation: Cb. Eap et al., PLASMA-LEVELS OF THE ENANTIOMERS OF THIORIDAZINE, THIORIDAZINE 2-SULFOXIDE, THIORIDAZINE 2-SULFONE, AND THIORIDAZINE 5-SULFOXIDE IN POOR AND EXTENSIVE METABOLIZERS OF DEXTROMETHORPHAN AND MEPHENYTOIN, Clinical pharmacology and therapeutics, 59(3), 1996, pp. 322-331
ANTIDEPRESSANTS AND DRUG-METABOLIZING-ENZYMES - EXPERT GROUP-REPORT
Authors: MEYER UA AMREIN R BALANT LP BERTILSSON L EICHELBAUM M GUENTERT TW HENAUER S JACKSON P LAUX G MIKKELSEN H PECK C POLLOCK BG PRIEST R SJOQVIST F DELINISTULA A
Citation: Ua. Meyer et al., ANTIDEPRESSANTS AND DRUG-METABOLIZING-ENZYMES - EXPERT GROUP-REPORT, Acta psychiatrica Scandinavica, 93(2), 1996, pp. 71-79
MOCLOBEMIDE AND FLUVOXAMINE COADMINISTRATION - A PROSPECTIVE-STUDY INHEALTHY-VOLUNTEERS TO INVESTIGATE THE POTENTIAL DEVELOPMENT OF THE SEROTONIN SYNDROME
Authors: WALLNOFER A GUENTERT TW ECKERNAS SA DINGEMANSE J
Citation: A. Wallnofer et al., MOCLOBEMIDE AND FLUVOXAMINE COADMINISTRATION - A PROSPECTIVE-STUDY INHEALTHY-VOLUNTEERS TO INVESTIGATE THE POTENTIAL DEVELOPMENT OF THE SEROTONIN SYNDROME, Human psychopharmacology, 10(1), 1995, pp. 25-31
CLINICAL PHARMACOKINETICS OF THE MONOAMINE OXIDASE-A INHIBITOR MOCLOBEMIDE
Authors: MAYERSOHN M GUENTERT TW
Citation: M. Mayersohn et Tw. Guentert, CLINICAL PHARMACOKINETICS OF THE MONOAMINE OXIDASE-A INHIBITOR MOCLOBEMIDE, Clinical pharmacokinetics, 29(5), 1995, pp. 292-332
MOCLOBEMIDE - RELATIONSHIPS BETWEEN DOSE, DRUG CONCENTRATION IN PLASMA, AND OCCURRENCE OF ADVERSE EVENTS
Authors: GUENTERT TW BANKEN L HILTON S HOLFORD NHG
Citation: Tw. Guentert et al., MOCLOBEMIDE - RELATIONSHIPS BETWEEN DOSE, DRUG CONCENTRATION IN PLASMA, AND OCCURRENCE OF ADVERSE EVENTS, Journal of clinical psychopharmacology, 15(4), 1995, pp. 84-94
MOCLOBEMIDE, A SUBSTRATE OF CYP2C19 AND AN INHIBITOR OF CYP2C19, CYP2D6, AND CYP1A2 - A PANEL STUDY
Authors: GRAM LF GUENTERT TW GRANGE S VISTISEN K BROSEN K
Citation: Lf. Gram et al., MOCLOBEMIDE, A SUBSTRATE OF CYP2C19 AND AN INHIBITOR OF CYP2C19, CYP2D6, AND CYP1A2 - A PANEL STUDY, Clinical pharmacology and therapeutics, 57(6), 1995, pp. 670-677
LACK OF AN IMPORTANT INFLUENCE OF CYP2D6 OXIDATION STATUS ON THE PHARMACOKINETICS OF MOCLOBEMIDE
Authors: GUENTERT TW GRANGE S BOCK J WALDBURGER R BIRNBOECK H HOFFMANNLAROCHE F
Citation: Tw. Guentert et al., LACK OF AN IMPORTANT INFLUENCE OF CYP2D6 OXIDATION STATUS ON THE PHARMACOKINETICS OF MOCLOBEMIDE, Clinical pharmacology and therapeutics, 57(2), 1995, pp. 151-151
MIXED LINEAR AND NONLINEAR DISPOSITION OF LAZABEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR OF MONOAMINE-OXIDASE-B
Authors: GUENTERT TW HOLFORD NHG PFEFEN JP DINGEMANSE J
Citation: Tw. Guentert et al., MIXED LINEAR AND NONLINEAR DISPOSITION OF LAZABEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR OF MONOAMINE-OXIDASE-B, British journal of clinical pharmacology, 37(6), 1994, pp. 545-551
PHARMACODYNAMICS OF LAZABEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR OF MONOAMINE-OXIDASE-B
Authors: HOLFORD NHG GUENTERT TW DINGEMANSE J KETTLER R
Citation: Nhg. Holford et al., PHARMACODYNAMICS OF LAZABEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR OF MONOAMINE-OXIDASE-B, British journal of clinical pharmacology, 37(6), 1994, pp. 553-557
MONOAMINE OXIDASE-A - PHARMACODYNAMICS IN HUMANS OF MOCLOBEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR
Authors: HOLFORD NHG GUENTERT TW DINGEMANSE J BANKEN L
Citation: Nhg. Holford et al., MONOAMINE OXIDASE-A - PHARMACODYNAMICS IN HUMANS OF MOCLOBEMIDE, A REVERSIBLE AND SELECTIVE INHIBITOR, British journal of clinical pharmacology, 37(5), 1994, pp. 433-439
REVERSIBLE INTERACTION OF MOCLOBEMIDE WITH CYP2D6 AND CYP2C9
Authors: GUENTERT TW GRAM LF GRANGE S BROSEN K
Citation: Tw. Guentert et al., REVERSIBLE INTERACTION OF MOCLOBEMIDE WITH CYP2D6 AND CYP2C9, Clinical pharmacology and therapeutics, 55(2), 1994, pp. 137-137
RELATIVE BIOAVAILABILITY OF ORAL DOSAGE FORMS OF TERAOXICAM
Authors: GUENTERT TW STEBLER T BANKEN L DEFOIN R SCHMITT M
Citation: Tw. Guentert et al., RELATIVE BIOAVAILABILITY OF ORAL DOSAGE FORMS OF TERAOXICAM, Arzneimittel-Forschung, 44-2(9), 1994, pp. 1051-1054
BIOAVAILABILITY OF INTRAMUSCULARLY ADMINISTERED TENOXICAM
Authors: STEBLER T GUENTERT TW
Citation: T. Stebler et Tw. Guentert, BIOAVAILABILITY OF INTRAMUSCULARLY ADMINISTERED TENOXICAM, Biopharmaceutics & drug disposition, 14(6), 1993, pp. 483-490
Risultati: 1-14 |